Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | TMPRSS4 | Q9NRS4 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18341136 | 0.91 | TMPRSS4 (0.53) | TRPV1MAPTTMPRSS4TSHRSMN1; SMN2 | |
| SCHEMBL330053 | 0.90 | TMPRSS4 (0.68) | TRPV1MAPTTMPRSS4TSHRSMN1; SMN2 | |
| SCHEMBL2700457 | 0.87 | TRPV1 (0.67) | TRPV1MAPTTSHRSMN1; SMN2CYP2C19 | |
| SCHEMBL130511 | 0.85 | TMPRSS4 (0.65) | TMPRSS4CYP2C19CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3496754 | 0.84 | TRPV1 (0.59) | TRPV1MAPTTMPRSS4TSHRSMN1; SMN2 | |
| SCHEMBL16707260 | 0.81 | TMPRSS4 (0.60) | TMPRSS4CYP2C19CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4498909 | 0.81 | POLB (0.53) | TRPV1MAPTTMPRSS4TSHRSMN1; SMN2 | |
| SCHEMBL330023 | 0.81 | TMPRSS4 (0.83) | TRPV1TMPRSS4TSHRSMN1; SMN2CHRNA7 | |
| SCHEMBL329943 | 0.80 | KCNMA1 (0.55) | MAPTTSHRSMN1; SMN2CYP2C19CYP3A4 | |
| SCHEMBL5063679 | 0.80 | CYP3A4 (0.56) | TRPV1MAPTTSHRSMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AEROMICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240360077-A1 | METHODS | AEROMICS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20220081391-A1 | METHODS | AEROMICS, INC. | 2022-03-17 | — | — | US | disclosed |
| CN-109512805-B | Compounds for the treatment of aquaporin mediated diseases | 埃罗米克斯公司 | 2021-12-31 | — | — | CN | disclosed |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AEROMICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20180334424-A1 | METHODS | AEROMICS, INC. | 2018-11-22 | — | — | US | disclosed |
| EP-2846787-B1 | Compounds for use in the treatment of aquaporin-mediated diseases | AEROMICS INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9994514-B2 | Methods of treating cerebral edema and spinal cord edema | AEROMICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9949991-B2 | Methods of treating aquaporin-mediated conditions | AEROMICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-1844766-B1 | Inhibitors against the production and release of inflammatory cytokines | INST MED MOLECULAR DESIGN INC (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334424-A1 | METHODS | AQP4, AQP1, AQP3 | TRPV1 1299/4885MAPT 1003/4885TMPRSS4 1257/4885 |
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AQP4, AQP1, AQP3 | TRPV1 904/4885MAPT 724/4885TMPRSS4 1043/4885 |
| US-20220081391-A1 | METHODS | AQP4, AQP1, AQP3 | TRPV1 1299/4885MAPT 1003/4885TMPRSS4 1257/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TRPV1 679/4885MAPT 1849/4885TMPRSS4 1813/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TRPV1 702/4885MAPT 2086/4885TMPRSS4 1647/4885 |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AQP4, AQP1, AQP3 | TRPV1 1102/4885MAPT 900/4885TMPRSS4 946/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TRPV1 702/4885MAPT 2086/4885TMPRSS4 1647/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TRPV1 702/4885MAPT 2086/4885TMPRSS4 1647/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | TRPV1 1156/4885MAPT 549/4885TMPRSS4 1444/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | TRPV1 1398/4885MAPT 2435/4885TMPRSS4 3292/4885 |
| US-20240360077-A1 | METHODS | AQP4, AQP1, AQP3 | TRPV1 1464/4885MAPT 1114/4885TMPRSS4 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.